Your browser doesn't support javascript.
loading
Allosteric regulation of AMP-activated protein kinase by adenylate nucleotides and small-molecule drugs.
de Souza Almeida Matos, Ana Laura; Oakhill, Jonathan S; Moreira, José; Loh, Kim; Galic, Sandra; Scott, John W.
Afiliación
  • de Souza Almeida Matos AL; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Oakhill JS; Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Australia.
  • Moreira J; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
  • Loh K; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Galic S; Protein Chemistry & Metabolism Unit, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Australia.
  • Scott JW; Protein Chemistry & Metabolism Unit, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Australia.
Biochem Soc Trans ; 47(2): 733-741, 2019 04 30.
Article en En | MEDLINE | ID: mdl-31000529
ABSTRACT
The AMP (adenosine 5'-monophosphate)-activated protein kinase (AMPK) is a key regulator of cellular and whole-body energy homeostasis that co-ordinates metabolic processes to ensure energy supply meets demand. At the cellular level, AMPK is activated by metabolic stresses that increase AMP or adenosine 5'-diphosphate (ADP) coupled with falling adenosine 5'-triphosphate (ATP) and acts to restore energy balance by choreographing a shift in metabolism in favour of energy-producing catabolic pathways while inhibiting non-essential anabolic processes. AMPK also regulates systemic energy balance and is activated by hormones and nutritional signals in the hypothalamus to control appetite and body weight. Failure to maintain energy balance plays an important role in chronic diseases such as obesity, type 2 diabetes and inflammatory disorders, which has prompted a major drive to develop pharmacological activators of AMPK. An array of small-molecule allosteric activators has now been developed, several of which can activate AMPK by direct allosteric activation, independently of Thr172 phosphorylation, which was previously regarded as indispensable for AMPK activity. In this review, we summarise the state-of-the-art regarding our understanding of the molecular mechanisms that govern direct allosteric activation of AMPK by adenylate nucleotides and small-molecule drugs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas Activadas por AMP Límite: Animals / Humans Idioma: En Revista: Biochem Soc Trans Año: 2019 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas Activadas por AMP Límite: Animals / Humans Idioma: En Revista: Biochem Soc Trans Año: 2019 Tipo del documento: Article País de afiliación: Dinamarca
...